The German government is considering limiting the price that drug companies can charge the country’s health care system for their latest medicines—a move that would curtail a lucrative, one-year amnesty from the country’s otherwise strict price controls.
from WSJ.com: US Business http://ift.tt/26iwt6Q
via IFTTT
No comments:
Post a Comment